{
    "clinical_study": {
        "@rank": "154562", 
        "arm_group": [
            {
                "arm_group_label": "Ramucirumab plus Docetaxel", 
                "arm_group_type": "Experimental", 
                "description": "Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes.  Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes."
            }, 
            {
                "arm_group_label": "Placebo plus Docetaxel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.  Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of ramucirumab in combination with\n      docetaxel in participants with Stage IV non-small cell lung cancer who have had disease\n      progression during or after one prior first-line platinum-based chemotherapy with or without\n      maintenance therapy for advanced/metastatic disease."
        }, 
        "brief_title": "A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-Small Cell Lung Cancer disease\n\n          -  Clinical stage IV or recurrent disease\n\n          -  One prior first-line platinum-based chemotherapy regimen with or without maintenance\n             therapy\n\n          -  For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the\n             epidermal growth factor receptor (EGFR) mutation status is known prior to\n             randomization\n\n          -  For participants with activating epidermal growth factor receptor (EGFR) mutation\n             ONLY, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI)\n             monotherapy (only one regimen in the setting of single use) should be utilized\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n\n          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors\n             (RECIST) version RECIST version 1.1\n\n          -  Adequate organ function\n\n          -  Estimated life expectancy of at least 3 months.\n\n        Exclusion Criteria:\n\n          -  Have undergone major surgery within 28 days prior to randomization or have planned\n             major surgery during study treatment\n\n          -  Receiving concurrent treatment with other anticancer therapy\n\n          -  Central nervous system disease other than stable and treated brain metastasis\n\n          -  Has major blood vessel invasion or encasement by cancer\n\n          -  Has intratumor cavitation\n\n          -  Has a history of uncontrolled thrombotic disorder\n\n          -  Is receiving therapeutic anticoagulation with drugs\n\n          -  Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs\n\n          -  Has a history of hemoptysis within 2 months prior to randomization\n\n          -  Has clinically relevant congestive heart failure\n\n          -  Has experienced any arterial thromboembolic event\n\n          -  Has uncontrolled arterial hypertension\n\n          -  Has had a serious or nonhealing wound or, ulcer\n\n          -  Has significant existing conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703091", 
            "org_study_id": "14658", 
            "secondary_id": "I4T-JE-JVCG"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ramucirumab plus Docetaxel", 
                "description": "Administered IV", 
                "intervention_name": "Ramucirumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LY 3009806", 
                    "IMC-1121B"
                ]
            }, 
            {
                "arm_group_label": "Placebo plus Docetaxel", 
                "description": "Administered IV", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ramucirumab plus Docetaxel", 
                    "Placebo plus Docetaxel"
                ], 
                "description": "Administered IV", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan", 
                        "zip": "464-8681"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "277 8577"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ehime", 
                        "country": "Japan", 
                        "zip": "791-0280"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "830-0011"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "060-8648"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "673-8558"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ishikawa", 
                        "country": "Japan", 
                        "zip": "920-8641"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan", 
                        "zip": "236-0051"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miyagi", 
                        "country": "Japan", 
                        "zip": "980-8574"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama", 
                        "country": "Japan", 
                        "zip": "700-8558"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "589-8511"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan", 
                        "zip": "362-0806"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan", 
                        "zip": "411-8777"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "135-8550"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yamaguchi", 
                        "country": "Japan", 
                        "zip": "755-0241"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Measured Progressive Disease or Death from Any Cause (estimated up to 28 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703091"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline  to Death from Any Cause (estimated up to 28 months)"
            }, 
            {
                "measure": "Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Participant Stops Study (estimated up to 28 months)"
            }, 
            {
                "measure": "Number of Participants who Achieve Best Overall Disease Response of Complete Response, Partial Response or Stable Disease (Disease Control Rate[DCR])", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Participant Stops Study (estimated up to 28 months)"
            }, 
            {
                "measure": "Change from Baseline in EuroQol 5-Dimensional Scale (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Participant Stops Study (estimated up to 28 months)"
            }, 
            {
                "measure": "Change from Baseline in Lung Cancer Symptom Scale (LCSS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Participant Stops Study (estimated up to 28 months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}